Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 11Unknown 2Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Head & Neck 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Pituitary Neoplasms 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Rosiglitazone × Clear all
NCT03309319 2017-10-13

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Huashan Hospital

Phase NA Unknown
24 enrolled
Endocrine

Pituitary Neoplasms

NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡